Despite an immediate need for more regulatory guidance and consumer safety provisions, the FDA has decided to punt any regulatory guidance with regard to CBD back to Congress. While the FDA has acknowledged the need for a new pathway to regulate these produces, it announced today that the current regulatory framework does not provide sufficient protections to regulate CBD. While they are working on a solution, this continued delay presents major concerns for manufacturers, consumers, advocates and stakeholders.